Test2learn Pharmacogenomics Certificate Program (2024) - August 16, 2024
Pharmacogenomic (PGx) information is in the FDA labeling for 300+ drugs and consensus clinical PGx guidelines have been published for over 70 commonly-used drugs. Several leading academic medical centers have launched implementation programs there is great interest in expanding these into the community setting, specifically into community pharmacies. Position statements from national organizations and several surveys of practicing clinicians demonstrate that they feel responsible for, and are eager to, deploy pharmacogenomics (PGx) in clinical practice. One such survey of community pharmacists by Tuteja et al reported all respondents “ had positive attitudes towards PGx and most (87%) felt it would decrease the number of adverse events, and optimize drug dosing. More than half (57%) felt that it was their role to counsel patients regarding PGx information. However, clinicians report low knowledge and confidence in using PGx information for adjusting dose or drug selection. This barrier must be overcome to achieve positive outcomes from new pharmacogenomics services.
Link For Recorded Materials: https://programs.test2learn.org/enrol/index.php?id=64 LOGIN: programreviewer PASSWORD: T2L-review24
Target Audience
Pharmacist
Nurse Practitioner
Nurse
Physician
Physician Assistant
Learning Objectives
Foundational Genetics Concepts (FG)
1. Explain basic genetics concepts using appropriate nomenclature.
2. Recognize the combined impact of genetic, behavioral, social, and environmental factors in the manifestation of disease and drug response.
3. Identify drug- and disease-associated genetic variations that facilitate development of prevention, diagnostic, and treatment strategies.
4. Differentiate between the clinical diagnosis of disease informed by genetics and the identification of genetic predisposition to disease.
5. Assess differences in genetic testing technologies, including sequencing and genotyping.
6. Recognize the legal protections against discrimination based on genetic test results.
Clinical PGx (CP)
1. Identify pharmacogenomic test results that are relevant to a patient’s care.
2. Interpret pharmacogenomic test results, including translating genotype to phenotype to drug therapy recommendation.
3. Determine the impact of genetic variation on pharmacokinetics and/or pharmacodynamics.
4. Identify medication-related problems that may be related to genetic variability, even when a pharmacogenomic test has not been done.
5. Recognize disease implications of pharmacogenomic test results and refer the patient to a genetics-trained healthcare provider when necessary.
6. Use family history to assess predisposition to disease and drug response.
7. Assess the quality and source of existing pharmacogenomic test results.
8. Distinguish between actionable and non-actionable pharmacogenomic test results using high-quality, evidence-based pharmacogenomics databases and clinical guidelines.
9. Integrate pharmacogenomic test results with other clinical variables to optimize medication therapy.
10. Recommend pharmacogenomic testing when appropriate.
11. Consider the cost, cost-effectiveness, and reimbursement issues relevant to pharmacogenomic tests and services.
12. Implement a pharmacogenomics-guided care plan in collaboration with the patient, caregivers, and other health professionals.
13. Document pharmacogenomic test results in the electronic health record.
14. Follow-up and monitor a pharmacogenomics-guided care plan.
15. Collaborate as a member of an interprofessional clinical pharmacogenomics team.
16. Identify patient populations that may be most likely to benefit from pharmacogenomic testing.
17. Identify genetic variations that predispose patients to adverse drug reactions and modify therapy accordingly to mitigate the risk.
18. Recognize the differences in pharmacogenomic allele frequencies among ancestry groups to guide appropriate test selection and maximize the appropriate use of medications in a population.
19. Educate patients and professional colleagues on the benefits and limitations of pharmacogenomics to optimize drug therapy.
20. Use a culturally-sensitive approach that considers potential ethical concerns when counseling patients about pharmacogenomic test results.
21. Use evidence-based resources and pharmacogenomics information to advance patient care.
22. Oversee clinical pharmacogenomics operations.
23. Fulfill a medication order considering the clinical implications of pharmacogenomics.
24. Create a written plan for continuous professional development in clinical pharmacogenomics.
Additional Information
Attachment | Size |
---|---|
CE_VAz.pptx | 157.71 KB |
Pharmacogenomic (PGx) information is in the FDA labeling for 300+ drugs and consensus clinical PGx guidelines have been published for over 70 commonly-used drugs. Several leading academic medical centers have launched implementation programs there is great interest in expanding these into the community setting, specifically into community pharmacies. Position statements from national organizations and several surveys of practicing clinicians demonstrate that they feel responsible for, and are eager to, deploy pharmacogenomics (PGx) in clinical practice. One such survey of community pharmacists by Tuteja et al reported all respondents “ had positive attitudes towards PGx and most (87%) felt it would decrease the number of adverse events, and optimize drug dosing. More than half (57%) felt that it was their role to counsel patients regarding PGx information. However, clinicians report low knowledge and confidence in using PGx information for adjusting dose or drug selection. This barrier must be overcome to achieve positive outcomes from new pharmacogenomics services.
Link For Recorded Materials: https://programs.test2learn.org/enrol/index.php?id=64 LOGIN: programreviewer PASSWORD: T2L-review24
Rachel Parker
James Coons, PharmD
Katherine Robinson, PharmD, MS, BCPS
Mylynda Massart, MD, PhD
Lisa Parker, PhD
Philip Empey, PharmD, PhD
Lucas Berenbrok, PharmD, MS
Kayla Rowe, PharmD
Jill Bates, PharmD, MS
Todd Skaar, MS, PhD
Kelly Caudle, PharmD, PhD, BCPS, FCCP
Robert Schuck, PharmD, PhD
Michelle Whirl-Carrillo, PhD
Jim Stevenson, PharmD, MS
Max Smith PharmD, BCPS
Emma Tillman, PharmD, PhD, FCCP
Sara Rogers, PharmD
Bonnie Balderose
Courtney Givens
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (ACPE)
This knowledge-based activity provides 20.0 contact hours of continuing pharmacy education credit.
Physician (CME)
The University of Pittsburgh School designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing (CNE)
The maximum number of hours awarded for this Continuing Nursing Education activity is 20.0 contact hours.
Physician Assistant (AAPA)
The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 20.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Other Healthcare Professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 20.00 AAPA Category I CME
- 20.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
- 20.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 20.00 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 20.00 Attendance